SEC Comment Letter 0000000000-24-012201 to Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257) (RADX)
Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257)
Date: Nov. 1, 2024 · CIK: 0001949257 · Accession: 0000000000-24-012201
AI Filing Summary & Sentiment
File numbers found in text: 001-41621
Letter
November 1, 2024 Riccardo Canevari Chief Executive Officer Radiopharm Theranostics Ltd Level 3, 62 Lygon Street, Carlton VIC 3053 Australia Re:Radiopharm Theranostics Ltd Amendment No. 6 to Registration Statement on Form 20FR12B Filed October 21, 2024 File No. 001-41621 Dear Riccardo Canevari: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response and any amendment you may file in response to this letter, we may have additional comments. Amendment No. 6 to Registration Statement on Form 20FR12B D. Risk Factors, page 1 1.Please include a risk factor discussing the going concern opinion issued by your auditors and the potential consequences with respect to raising capital. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
November 1, 2024 Page 2
Please contact Gary Newberry at 202-551-3761 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Lauren Hamill at 303-844-1008 or Suzanne Hayes at 202-551-3675 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Alberto Pacchioni
Show Raw Text
November 1, 2024
Riccardo Canevari
Chief Executive Officer
Radiopharm Theranostics Ltd
Level 3, 62 Lygon Street, Carlton VIC 3053
Australia
Re:Radiopharm Theranostics Ltd
Amendment No. 6 to Registration Statement on Form 20FR12B
Filed October 21, 2024
File No. 001-41621
Dear Riccardo Canevari:
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response and any amendment you may file in response to this
letter, we may have additional comments.
Amendment No. 6 to Registration Statement on Form 20FR12B
D. Risk Factors, page 1
1.Please include a risk factor discussing the going concern opinion issued by your
auditors and the potential consequences with respect to raising capital.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
November 1, 2024
Page 2
Please contact Gary Newberry at 202-551-3761 or Kevin Vaughn at 202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please contact Lauren Hamill at 303-844-1008 or Suzanne Hayes at 202-551-3675
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Alberto Pacchioni